Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29398859 | 1.00 | MDM2 (0.52) | MDM2IDO1MDM4TP53KMT2A | |
| SCHEMBL30757738 | 1.00 | MDM2 (0.52) | MDM2IDO1MDM4TP53KMT2A | |
| SCHEMBL1000225 | 1.00 | MDM2 (0.52) | MDM2IDO1MDM4TP53KMT2A | |
| SCHEMBL999883 | 1.00 | MDM2 (0.52) | MDM2IDO1MDM4TP53KMT2A | |
| SCHEMBL3348411 | 1.00 | MDM2 (0.52) | MDM2IDO1MDM4TP53KMT2A | |
| SCHEMBL38664164 | 0.96 | MDM2 (0.54) | MDM2IDO1MDM4TP53TLR2 | |
| SCHEMBL12757436 | 0.96 | MDM2 (0.54) | MDM2IDO1MDM4TP53TLR2 | |
| SCHEMBL4600320 | 0.96 | MDM2 (0.54) | MDM2IDO1MDM4TP53TLR2 | |
| SCHEMBL29687581 | 0.96 | MDM2 (0.54) | MDM2IDO1MDM4TP53TLR2 | |
| SCHEMBL29382463 | 0.96 | MDM2 (0.54) | MDM2IDO1MDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4719381-A1 | LIGAND-POLAR DRUG CONJUGATES | Tripartite Therapeutics Inc. (TW) | 2026-04-08 | — | — | EP | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| WO-2025131101-A1 | POLYPEPTIDE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 上海多米瑞生物技术有限公司 | 2025-06-26 | — | — | WO | disclosed |
| CN-120192363-A | Polypeptide compound, pharmaceutical composition thereof and application thereof | 上海多米瑞生物技术有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-111225688-B | FBSA-based therapy and radiological imaging conjugates targeting carbonic anhydrase-positive cancers | 普渡研究基金会 | 2025-06-17 | — | — | CN | disclosed |
| CN-114585637-B | MASP-inhibitory compounds and uses thereof | 拜耳公司 | 2025-04-15 | — | — | CN | disclosed |
| EP-3672615-B1 | FBSA-BASED THERAPEUTIC AND RADIOIMAGING CONJUGATES TARGETING CARBONIC ANHYDRASE POSITIVE CANCERS | PURDUE RESEARCH FOUNDATION (US) | 2025-04-02 | — | — | EP | disclosed |
| US-20250090698-A1 | SMALL MOLECULE INHIBITORS FOR EARLY DIAGNOSIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN CANCERS AND NEURODEGENERATIVE DISEASES | INDIAN INSTITUTE OF TECH INDORE (IN) | 2025-03-20 | — | — | US | disclosed |
| US-11674136-B2 | DNA-templated macrocycle library | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-13 | — | — | US | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-11524082-B2 | FBSA-based therapeutic and radioimaging conjugates targeting carbonic anhydrase positive cancers | PURDUE RESEARCH FOUNDATION (US) | 2022-12-13 | — | — | US | disclosed |
| WO-2022234867-A1 | SULFONAMIDE HAVING MMP 7-INHIBITING ACTION | 大正製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| WO-2022220725-A1 | LPXH INHIBITORS AS ANTI-INFECTIVE AGENTS | ZAMARATSKI EDOUARD (SE) | 2022-10-20 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| CN-114585637-A | MASP inhibiting compounds and uses thereof | 拜耳公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-3966226-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2022-03-16 | — | — | EP | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | MDM2 1513/4885IDO1 1732/4885MDM4 2629/4885 |
| US-11674136-B2 | DNA-templated macrocycle library | IDE, IAPP, POLRMT | MDM2 938/4885IDO1 2676/4885MDM4 1827/4885 |
| US-11524082-B2 | FBSA-based therapeutic and radioimaging conjugates targeting carbonic anhydrase positive cancers | CA9, CA13, CA14 | MDM2 3446/4885IDO1 3094/4885MDM4 3806/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | MDM2 1513/4885IDO1 1732/4885MDM4 2629/4885 |
| US-20250090698-A1 | SMALL MOLECULE INHIBITORS FOR EARLY DIAGNOSIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN CANCERS AND NEURODEGENERATIVE DISEASES | KLK3, SPAG5, DNPEP | MDM2 3533/4885IDO1 2480/4885MDM4 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.